Apixaban versus warfarin in Atrial Fibrillation [1]

New England Journal of Medicine

Volumn 366, Issue 1, 2012, Pages 88-90

  Vassiliou, Vassilios S ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APIXABAN; WARFARIN; BLOOD CLOTTING FACTOR; DABIGATRAN; FRESH FROZEN PLASMA; RIVAROXABAN; VITAMIN K GROUP; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE;

ANTICOAGULATION; BLEEDING; CLINICAL TRIAL (TOPIC); CONTROL GROUP; EUROPE; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; LETTER; METHODOLOGY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; STROKE; THROMBOEMBOLISM; TREATMENT OUTCOME; BLOOD COMPONENT THERAPY; DRUG MECHANISM; EMERGENCY SURGERY; LIVER METABOLISM; UNSPECIFIED SIDE EFFECT; DRUG ANTAGONISM; FEMALE; MALE; NOTE;

ANTICOAGULANTS; ATRIAL FIBRILLATION; FACTOR XA; FEMALE; HUMANS; MALE; PYRAZOLES; PYRIDONES; STROKE; THROMBOEMBOLISM; WARFARIN;

EID: 84855748942     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1112500     Document Type: Letter

References (2)

1. Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-92.
2. Wieloch M, Själander A, Frykman V, Rosenqvist M, Eriksson N, Svensson PJ. Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA. Eur Heart J 2011;32:2282-9.